Pharmacological evaluation of synthetic cannabinoids i

Forensic Toxicology

34, 329-343

DOI: 10.1007/s11419-016-0320-2

Citation Report

#	Article	IF	Citations
1	Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. ACS Chemical Neuroscience, 2016, 7, 1241-1254.	3.5	214
2	Identification and quantification of synthetic cannabinoids in â€œspice-likeâ€•herbal mixtures: Update of the German situation for the spring of 2016. Forensic Science International, 2016, 269, 31-41.	2.2	45
3	Synthetic Pot: Not Your Grandfatherâ€™s Marijuana. Trends in Pharmacological Sciences, 2017, 38, 257-276.	8.7	78
4	Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2013â€“2016: A Review. Journal of Analytical Toxicology, 2017, 41, 573-610.	2.8	128
5	Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18. Clinical Chemistry, 2017, 63, 1753-1763.	3.2	11
6	Chemical Tools for Studying Lipid-Binding Class A G Proteinâ€“Coupled Receptors. Pharmacological Reviews, 2017, 69, 316-353.	16.0	20
7	Elucidation of the fluorine substitution position on the phenyl ring of synthetic cannabinoids by electron ionization-triple quadrupole mass spectrometry. Japanese Journal of Forensic Science and Technology, 2017, 22, 133-143.	0.1	5
8	Translational Research and Innovation in Human and Health Science. Annals of Medicine, 2018, 50, S10-S170.	3.8	3
9	Analysis of the pharmacological properties of JWH-122 isomers and THJ-2201, RCS-4 and AB-CHMINACA in HEK293T cells and hippocampal neurons. European Journal of Pharmacology, 2018, 823, 96-104.	3.5	10
10	The chemistry and pharmacology of synthetic cannabinoid SDBâ€006 and its regioisomeric fluorinated and methoxylated analogs. Drug Testing and Analysis, 2018, 10, 1099-1109.	2.6	12
11	Pharmacological evaluation of new constituents of â€œSpiceâ€• synthetic cannabinoids based on indole, indazole, benzimidazole and carbazole scaffolds. Forensic Toxicology, 2018, 36, 385-403.	2.4	88
12	Structural characterization and pharmacological evaluation of the new synthetic cannabinoid CUMYLâ€PEGACLONE. Drug Testing and Analysis, 2018, 10, 597-603.	2.6	37
13	Î”9-Tetrahydrocannabinol-like discriminative stimulus effects of five novel synthetic cannabinoids in rats. Psychopharmacology, 2018, 235, 673-680.	3.1	12
14	Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review. European Neuropsychopharmacology, 2018, 28, 1289-1304.	0.7	25
15	Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Î”9-THC. Frontiers in Pharmacology, 2018, 9, 1084.	3.5	20
16	Discovery of High-Affinity Cannabinoid Receptors Ligands through a 3D-QSAR Ushered by Scaffold-Hopping Analysis. Molecules, 2018, 23, 2183.	3.8	29
17	The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.9	42
18	The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins. Handbook of Experimental Pharmacology, 2018, 252, 165-190.	1.8	73

#	Article	IF	Citations
19	Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection. Journal of Pharmaceutical and Biomedical Analysis, 2018, 157, 27-35.	2.8	21
20	Psychodysleptica. , 2018, , 1-392.		0
21	The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution. Handbook of Experimental Pharmacology, 2018, 252, 191-226.	1.8	64
22	Psychosis and synthetic cannabinoids. Psychiatry Research, 2018, 268, 400-412.	3.3	48
23	In vitro determination of the efficacy of illicit synthetic cannabinoids at CB₁ receptors. British Journal of Pharmacology, 2019, 176, 4653-4665.	5.4	46
24	In vitro metabolism of the synthetic cannabinoids PXâ€1, PXâ€2, and PXâ€3 by highâ€resolution mass spectrometry and their clearance rates in human liver microsomes. Rapid Communications in Mass Spectrometry, 2019, 33, 1816-1825.	1.5	11
25	Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists. Biochemical Pharmacology, 2019, 169, 113623.	4.4	70
26	Detection of the recently emerged synthetic cannabinoid 4Fâ€MDMBâ€BINACA in â€œlegal highâ€•products and human urine specimens. Drug Testing and Analysis, 2019, 11, 1377-1386.	2.6	44
28	Cytotoxicity of the synthetic cannabinoids 5C-AKB48, 5F-MDMB-PINACA, ADB-CHMINACA, MDMB-CHMICA and NM-2201 in A549 and TR146 cell lines. Forensic Toxicology, 2019, 37, 398-411.	2.4	2
29	New-generation azaindole-adamantyl-derived synthetic cannabinoids. Forensic Toxicology, 2019, 37, 350-365.	2.4	11
30	The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5Fâ€PYâ€PICA, 5Fâ€PYâ€PINACA, and their analogs. Drug Testing and Analysis, 2019, 11, 976-989.	2.6	17
31	Evaluation of the tubing material and physical dimensions on the performance of extraction columns for on-line sample preparation-LCâ€“MS/MS. Journal of Chromatography A, 2019, 1597, 18-27.	3.7	9
32	Death cases involving certain new psychoactive substances: A review of the literature. Forensic Science International, 2019, 298, 186-267.	2.2	97
34	Specialized Ruthenium Olefin Metathesis Catalysts Bearing Bulky Unsymmetrical NHC Ligands: Computations, Synthesis, and Application. ACS Catalysis, 2019, 9, 587-598.	11.2	50
35	Ion mobility spectrometry as a fast screening tool for synthetic cannabinoids to uncover drug trafficking in jail via herbal mixtures, paper, food, and cosmetics. Drug Testing and Analysis, 2019, 11, 833-846.	2.6	36
36	Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?. American Journal of Emergency Medicine, 2019, 37, 1846-1849.	1.6	7
37	Synthetic cannabinoid receptor agonists: classification and nomenclature. Clinical Toxicology, 2020, 58, 82-98.	1.9	64
38	Evidence of enzyme-mediated transesterification of synthetic cannabinoids with ethanol: potential toxicological impact. Forensic Toxicology, 2020, 38, 95-107.	2.4	5

#	Article	IF	Citations
39	Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds. ACS Pharmacology and Translational Science, 2020, 3, 285-295.	4.9	41
40	Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication. British Journal of Clinical Pharmacology, 2020, 86, 429-436.	2.4	24
41	Design and synthesis of fluorescent ligands for the detection of cannabinoid type 2 receptor (CB2R). European Journal of Medicinal Chemistry, 2020, 188, 112037.	5.5	14
42	Adding more â€œspiceâ€• to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists. Drug Testing and Analysis, 2020, 12, 297-315.	2.6	23
43	Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA. ACS Chemical Neuroscience, 2020, 11, 3672-3682.	3.5	14
44	Largeâ€Scale Synthesis of a Niche Olefin Metathesis Catalyst Bearing an Unsymmetrical Nâ€Heterocyclic Carbene (NHC) Ligand and its Application in a Green Pharmaceutical Context. Chemistry - A European Journal, 2020, 26, 15708-15717.	3.3	9
45	The short-acting synthetic cannabinoid AB-FUBINACA induces physical dependence in mice. Drug and Alcohol Dependence, 2020, 214, 108179.	3.2	5
46	hiPSC-Based Model of Prenatal Exposure to Cannabinoids: Effect on Neuronal Differentiation. Frontiers in Molecular Neuroscience, 2020, 13, 119.	2.9	14
47	The Synthetic Cannabinoids THJ-2201 and 5F-PB22 Enhance In Vitro CB1 Receptor-Mediated Neuronal Differentiation at Biologically Relevant Concentrations. International Journal of Molecular Sciences, 2020, 21, 6277.	4.1	16
48	The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review. Critical Reviews in Toxicology, 2020, 50, 359-382.	3.9	91
49	Discovery of Tricyclic Xanthines as Agonists of the Cannabinoid-Activated Orphan G-Protein-Coupled Receptor GPR18. ACS Medicinal Chemistry Letters, 2020, 11, 2024-2031.	2.8	16
50	Differential activation of G proteinâ€mediated signaling by synthetic cannabinoid receptor agonists. Pharmacology Research and Perspectives, 2020, 8, e00566.	2.4	16
51	Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. Biochemical Pharmacology, 2020, 175, 113871.	4.4	35
52	In Silico Infrared Characterization of Synthetic Cannabinoids by Quantum Chemistry and Chemometrics. Journal of Chemical Information and Modeling, 2020, 60, 2100-2114.	5.4	6
53	Discrimination of synthetic cannabinoids in herbal matrices and of cathinone derivatives by portable and laboratory-based Raman spectroscopy. Forensic Chemistry, 2020, 19, 100241.	2.8	19
54	In vitro metabolic profiles of adamantyl positional isomers of synthetic cannabinoids. Forensic Toxicology, 2021, 39, 26-44.	2.4	3
55	Synthetic cannabinoid receptor agonists: Analytical profiles and development of QMPSB, QMMSB, QMPCB, 2Fâ€QMPSB, QMiPSB, and SGTâ€233. Drug Testing and Analysis, 2021, 13, 175-196.	2.6	9
56	Synthetic Cannabinoids 5F-QUPIC and MDMB-CHMICA in Plant Material â€“ Identification and Quantification by Gas Chromatography â€“ Mass Spectrometry (GC-MS), Nuclear Magnetic Resonance (NMR), and High-Performance Liquid Chromatography with Diode Array Detection (HPLC-DAD). Analytical Letters, 2021, 54, 2600-2610.	1.8	2

#	Article	IF	Citations
57	A Systematic Study of the In Vitro Pharmacokinetics and Estimated Human In Vivo Clearance of Indole and Indazole-3-Carboxamide Synthetic Cannabinoid Receptor Agonists Detected on the Illicit Drug Market. Molecules, 2021, 26, 1396.	3.8	15
58	Modern approaches to the development of synthetic cannabinoid receptor probes. Pharmacology Biochemistry and Behavior, 2021, 203, 173119.	2.9	8
59	Effects of prenatal synthetic cannabinoid exposure on the cerebellum of adolescent rat offspring. Heliyon, 2021, 7, e06730.	3.2	6
60	Molecular Mechanisms of Action of Novel Psychoactive Substances (NPS). A New Threat for Young Drug Users with Forensic-Toxicological Implications. Life, 2021, 11, 440.	2.4	11
61	Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMBâ€4enâ€PICA, MDMBâ€4enâ€PINACA, ADBâ€4enâ€PINACA, and MMBâ€4CNâ€BUTINACA using a combination of binding and different CB₁ receptor activation assays: Part Iâ€”Synthesis, analytical characterization, and binding affinity for human CB₁ receptors. Drug Testing and Analysis, 2021, 13, 1383-1401.	2.6	19
62	Synthetic cannabinoids in e-liquids: A proton and fluorine NMR analysis from a conventional spectrometer to a compact one. Forensic Science International, 2021, 324, 110813.	2.2	10
63	Herbal Highs: Review on Psychoactive Effects and Neuropharmacology. Current Neuropharmacology, 2017, 15, 750-761.	2.9	36
64	NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?. ACS Chemical Neuroscience, 2021, 12, 4020-4036.	3.5	7
66	Synthesis of nine potential synthetic cannabinoid metabolites with a 5F-4OH pentyl side chain from a scalable key intermediate. Synthetic Communications, 2021, 51, 776-785.	2.1	3
67	Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights. Current Pharmaceutical Design, 2022, 28, 2603-2617.	1.9	13
68	Involuntary MDMB-4en-PINACA intoxications following cannabis consumption: clinical and analytical findings. Clinical Toxicology, 2022, 60, 458-463.	1.9	3
69	Quantifying the Kinetics of Signaling and Arrestin Recruitment by Nervous System G-Protein Coupled Receptors. Frontiers in Cellular Neuroscience, 2021, 15, 814547.	3.7	10
70	Adulteration of lowâ€deltaâ€9â€tetrahydrocannabinol products with synthetic cannabinoids: Results from drug checking services. Drug Testing and Analysis, 2022, 14, 1026-1039.	2.6	12
72	Analytical findings in a non-fatal intoxication with the synthetic cannabinoid 5F-ADB (5F-MDMB-PINACA): a case report. International Journal of Legal Medicine, 2022, 136, 577-589.	2.2	6
73	Defining Steric Requirements at CB₁ and CB₂ Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues. ACS Chemical Neuroscience, 2022, 13, 1281-1295.	3.5	6
78	A Comparison of Acute Neurocognitive and Psychotomimetic Effects of a Synthetic Cannabinoid and Natural Cannabis at Psychotropic Dose Equivalence. Frontiers in Psychiatry, 2022, 13, .	2.6	3
79	Development of an Indole-Amide-Based Photoswitchable Cannabinoid Receptor Subtype 1 (CB₁R) â€œCis-Onâ€•Agonist. ACS Chemical Neuroscience, 2022, 13, 2410-2435.	3.5	8
80	Minors and young adultâ€™s hospitalizations after â€œchimiqueâ€•consumption in Mayotte Island: which substances are involved?. Therapie, 2022, , .	1.0	3

#	Article	IF	Citations
83	Design, synthesis, and structureâ€“activity relationships of diindolylmethane derivatives as cannabinoid CB₂ receptor agonists. Archiv Der Pharmazie, 2023, 356, .	4.1	1
84	Off-target pharmacological profiling of synthetic cannabinoid receptor agonists including AMB-FUBINACA, CUMYL-PINACA, PB-22, and XLR-11. Frontiers in Psychiatry, 0, 13, .	2.6	2
85	Comprehensive Characterization of a Systematic Library of Alkyl and Alicyclic Synthetic Cannabinoids Related to CUMYL-PICA, CUMYL-BUTICA, CUMYL-CBMICA, and CUMYL-PINACA. ACS Chemical Neuroscience, 0, , .	3.5	0
86	The novel psychoactive substances epidemic: A scientometric perspective. Addiction Neuroscience, 2023, 5, 100060.	1.3	8
87	Synthesis, relative configuration and CB1 receptor affinity studies for a set of 1,2,3-triazole derivatives. Journal of Molecular Structure, 2023, 1282, 135223.	3.6	0
88	Benzydamineâ€”An Affordable Over-the-Counter Drug with Psychoactive Propertiesâ€”From Chemical Structure to Possible Pharmacological Properties. Pharmaceuticals, 2023, 16, 566.	3.8	4
89	GPR18 and GPR55-related Ligands Serving as Antagonists or Agonists: Current Situation, Challenges and Perspectives. Medicinal Chemistry, 2023, 19, .	1.5	0
90	Functional profile of synthetic cannabinoid receptor agonists: Exploring cannabinoid and noncannabinoid targets. , 2023, , 383-393.		0
91	Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs. Biomedicine and Pharmacotherapy, 2023, 164, 114934.	5.6	0
92	Synthetic cannabinoid receptor agonists: An overview. , 2023, , 493-504.		0
93	Synthetic cannabinoids impact on cognitive functions. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2023, 59, .	1.0	0
94	Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid <scp>CB₂</scp> receptor. Pharmacology Research and Perspectives, 2023, 11, .	2.4	1
95	The synthetic cannabinoids menace: a review of health risks and toxicity. European Journal of Medical Research, 2024, 29, .	2.2	0
96	Verkehrsmedizin. , 2023, , 901-980.		0